FLT3 overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or codon 835-836 mutations: A pilot study

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1201-1207

  Lilakos, K ^a   Viniou, Nora Athina ^a,b   Mavrogianni, D ^a   Vassilakopoulos, T P ^a   Dimopoulou, M N ^a   Plata, E ^a   Angelopoulou, M K ^a   Variami, E ^a   Stavrogianni, N ^a   Liapi, D ^a   Xilouri, I ^a   Galanopoulos, A ^a   Ageloudi, M ^a   Panayiotidis, P ^a   Voulgarelis, M ^a   Rombos, J ^a   Meletis, J ^a   Yataganas, X ^a   Pangalis, G A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b NONE   (Greece)

Author keywords

APL; FLT3 mutations; FLT3 overexpression; Tyrosine kinase inhibitors

Indexed keywords

CYTARABINE; ETOPOSIDE; FLT3 LIGAND; IDARUBICIN; METHOTREXATE; MITOXANTRONE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CODON; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MONONUCLEAR CELL; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CODON; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PILOT PROJECTS; POINT MUTATION; RNA, MESSENGER; TANDEM REPEAT SEQUENCES;

EID: 33645833694     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Warrell RP Jr, de The H, Wang ZY and Degos L: Acute promyelocytic leukemia. N Engl J Med 15: 177-189, 1993.
2. Melnick A and Licht JD: Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 15: 3167-3215, 1999.
3. Grignani F, Ferrucci PF, Testa U et al: The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 13: 423-431, 1993.
4. Rousselot P, Hardas B, Patel A et al: The PML-RAR alpha gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 9: 545-551, 1994.
5. Brown D, Kogan S, Lagasse E et al: A PML-RAR alpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 18: 2551-2556, 1997.
6. Grisolano JL, Wesselschmidt RL, Pelicci PG and Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences. Blood 89: 376-387, 1997.
7. He LZ, Tribioli C, Rivi R et al: Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice Proc Natl Acad Sci USA 94: 5302-5307, 1997.
8. Muench MO, Roncarolo MG, Menon S et al: FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 85: 963-972, 1995.
9. Molineux G, McCrea C, Yan XQ, Kerzic P and McNiece I: Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential. Blood 89: 3998-4004, 1997.
10. Shurin MR, Esche C and Lotze MT: FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 9: 37-48, 1998.
11. Gilliland DG and Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 100: 1532-1542, 2002.
12. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature 411: 355-365, 2001.
13. Yokota S, Kiyoi H, Nakao M et al: Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11: 1605-1609, 1997.
14. Kottaridis PD, Gale RE, Frew ME et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752-1759, 2001.
15. Yamamoto Y, Kiyoi H, Nakano Y et al: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439, 2001.
16. Schnittger S, Schoch C, Dugas M et al: Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100: 59-66, 2002.
17. Kiyoi H, Towatari M, Yokota S et al: Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12: 1333-1337, 1998.
18. Nakao M, Yokota S, Iwai T et al: Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918, 1996.
19. Furitsu T, Tsujimura T, Tono T et al: Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92: 1736-1744, 1993.
20. Beghini A, Peterlongo P, Ripamonti CB et al: C-kit mutations in core binding factor leukemias. Blood 95: 726-727, 2000.
21. Fenski R, Flesch K, Serve S et al: Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol 108: 322-330, 2000.
22. Hayakawa F, Towatari M, Kiyoi H et al: Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19: 624-631, 2000.
23. Thiede C, Steudel C, Mohr B et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326-4335, 2002.
24. Abu-Duhier FM, Goodeve AC, Wilson GA et al: FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 111: 190-195, 2000.
25. Shih LY, Kuo MC, Liang DC et al: Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia. Cancer 98: 1206-1216, 2003.
26. Drexler HG: Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 10: 588-599, 1996.
27. Rosnet O, Buhring HJ, Marchetto S et al: Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 10: 238-248, 1996.
28. Meierhoff G, Dehmel U, Gruss HJ et al: Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 9: 1368-1372, 1995.
29. Ozeki K, Kiyoi H, Hirose Y et al: Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103: 1901-1908, 2004.
30. Gale RE, Hills R, Pizzey AR et al: The relationship between FLT3 mutation status, biological characteristics and response to targeted therapy in acute promyelocytic leukemia. Blood, prepublished online 16 August 2005.
31. van Dongen JJ, Macintyre EA, Gabert JA et al: Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13: 1901-1928, 1999.
32. Nakao M, Yokota S, Iwai T et al: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918, 1996.
33. Yamamoto Y, Kiyoi H, Nakano Y et al: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97: 2434-2439, 2001.
34. Emig M, Saussele S, Wittor H et al: Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13: 1825-1832, 1999.
35. Beillard E, Pallisgaard N, van der Velden VH et al: Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia 17: 2474-2486, 2003.
36. Zipper H, Brunner H, Bernhagen J and Vitzthum F: Investigations on DNA intercalation and surface binding by SYBR Green I, its structure determination and methodological implications. Nucleic Acids Res 32: e103, 2004.
37. Libura M, Asnafi V, Tu A et al: FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood 102: 2198-2204, 2003.
38. Kiyoi H, Naoe T, Yokota S et al: Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11: 1447-1452, 1997.
39. Sohal J, Phan VT, Chan PV et al: A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101: 3188-3197, 2003.
40. Rosnet O, Stephenson D, Mattei MG et al: Close physical linkage of the FLT1 and FLT3 genes on chromosome 13 in man and chromosome 5 in mouse. Oncogene 8: 8173-8179, 1993.
41. Tse KF, Mukherjee G and Small D: Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14: 1766-1776, 2000.
42. Schichman SA, Caligiuri MA, Gu Y et al: ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci USA 91: 6236-6239, 1994.
43. Noguera NI, Breccia M, Divona M et al: Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 16: 2185-2189, 2002.
44. Caligiuri MA, Strout MP, Schichman SA et al: Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 56: 1418-1425, 1996.
45. Kainz B, Fonatsch C, Schwarzinger I, Sperr WR, Jager U and Gaiger A: Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia. Haematologica 90: 695-696, 2005.
46. Schnittger S, Kinkelin U, Schoch C et al: Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 14: 796-804, 2000.
47. Christiansen DH and Pedersen-Bjergaard J: Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy. Leukemia 15: 1848-1851, 2001.
48. Jamal R, Taketani T, Taki T et al: Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer 31: 187-190, 2001.
49. Armstrong SA, Kung AL, Mabon ME et al: Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3: 173-183, 2003.
50. Drexler HG, Meyer C and Quentmeier H: Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma 33: 83-91, 1999.
51. Eder M, Hemmati P, Kalina U et al: Effects of FLT3 ligand and interleukin-7 on in vitro growth of acute lymphoblastic leukemia cells. Exp Hematol 24: 371-377, 1996
52. Sawyers CL: Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer Cell 1: 413-415, 2002.
53. Martinelli G, Piccaluga PP and Lo Coco F: FLT3 inhibition as tailored therapy for acute myeloid leukemia. Haematologica 88: 4-8, 2003.